ClinicalTrials.gg
Active, not recruitingNCT05612035Updated Nov 13, 2026

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

A Phase 2 interventional study of Frespaciguat and Placebo in Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 85 sites in 19 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Updated Nov 13, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 397 studies in Hypertension, Pulmonary with a site in United States — 73 open to participants now, 87 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Enrollment
71st of 286
129 · median 30
Started
2023
with 14 others
Phase 2
93 of 397
13 open now
Primary completion
2026-04
later than 13 of 85 live
Registered
325th of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 71st largest by enrollment of the 286 interventional ones that give a count, is one of 15 that started in 2023, is one of 93 in phase 2, reaches primary completion later than 13 of the 85 other live ones, and was the 325th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

73 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.

03

Conditions studied

  • Pulmonary Hypertension
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The key inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • Has Group 3.1 pulmonary hypertension (PH-COPD) as defined by the Clinical Classification of Pulmonary Hypertension.
  • Has a right heart catheterization (RHC) at screening or historical RHC within 12 months before screening that meets hemodynamic criteria.
  • Has a physician diagnosis of obstructive lung disease on pulmonary function testing (PFT) performed at screening.
  • Has a WHO Functional Class assessment of Class II to IV.
  • If on supplemental oxygen, the regimen must be stable.
  • Has stable and optimized chronic, baseline COPD-specific therapy.
  • If on PDE5 inhibitor, has stable concomitant use (initiated at least 3 months prior to randomization and no change in drug or dosage for at least 3 months prior to randomization) and changes to PDE5 inhibitor dosing is not anticipated during the 24 week Base Period.
  • If on antihypertensives and/or a diuretic regimen has stable concomitant use.
  • If on anticoagulants has stable concomitant use.
  • Is of any sex/gender from 40 to 85 years of age inclusive.
  • Female is not pregnant or breastfeeding, and is not of or uses acceptable method or abstains from sexual intercourse, or has a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention, or whose history and sexual activity has been reviewed by the investigator.

Exclusion criteria

Exclusion criteria:

  • Has Group 1 pulmonary arterial hypertension (PAH), Groups 2, 4 or 5 pulmonary hypertension (PH).
  • Has non- related Group 3 PH.
  • Has evidence of untreated more than mild obstructive sleep apnea.
  • Has significant left heart disease.
  • Expects to receive a lung and/or heart transplant from screening through the end of the 24 week Base Period.
  • Has evidence of a resting oxygen saturation (SpO2) \< 88%.
  • Has experienced a moderate or severe COPD exacerbation within 2 months before randomization.
  • Has experienced right heart failure within 2 months before randomization.
  • Has uncontrolled tachyarrhythmia.
  • Has acute coronary syndrome, undergone coronary artery bypass graft, or percutaneous coronary intervention within 2 months before randomization.
  • Has evidence of significant chronic renal insufficiency.
  • Has evidence of chronic liver disease, portal hypertension, cirrhosis, or hepatic abnormalities.
  • Initiated a pulmonary rehabilitation program within 2 months before randomization.
  • Has impairments that limit the ability to perform 6MWT.
  • Has history of cancer.
  • Is a user of illicit drugs or has a recent history of drug/alcohol abuse or dependence.
  • Has used PAH-specific therapies within 2 months of randomization.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Frespaciguat

    Participants with PH-COPD will receive 380 µg of frespaciguat as an oral inhalation once daily for 24 weeks (base period) and thereafter for up to 42 months (optional extension period).

    Drug: Frespaciguat

  • Placebo comparator
    Placebo

    Participants with PH-COPD will receive matching placebo as an oral inhalation once daily for 24 weeks (base period) and then 380 µg of frespaciguat as an oral inhalation once daily for up to 42 months (optional extension period).

    Drug: Frespaciguat · Drug: Placebo

Interventions

  • Frespaciguat 380 µg administered as dry powder inhalation once daily.

    Also known as: MK-5475

  • DrugPlacebo

    Placebo administered as dry powder inhalation once daily.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in 6-minute Walk Distance (6MWD) at Week 24

    6MWD is assessed using the 6-minute walk test (6MWT).

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Mean Change From Baseline in 6MWD at Week 12

    6MWD is assessed using the 6-minute walk test (6MWT).

    Time frame: Baseline and Week 12

  2. Mean Change From Baseline in N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP) at Week 12

    NT-proBNP was measured at baseline and Week 12.

    Time frame: Baseline and Week 12

  3. Mean Change From Baseline in NT-ProBNP at Week 24

    NT-proBNP was measured at baseline and Week 24

    Time frame: Baseline and Week 24

  4. Percentage of Participants Whose World Health Organization-Functional Class (WHO-FC) Does not Worsen Relative to Baseline at Week 12

    Participants are assigned one of four WHO-FC, dependent on limits of physical activity. As WHO-FC increases from I to IV, limits of physical activity increase.

    Time frame: Baseline and Week 12

  5. Percentage of Participants Whose WHO-FC Does not Worsen Relative to Baseline at Week 24

    Participants are assigned one of four WHO-FC, dependent on limits of physical activity. As WHO-FC increases from I to IV, limits of physical activity increase.

    Time frame: Baseline and Week 24

  6. Percentage of Participants With One or More Adverse Events (AEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to Week 206

  7. Percentage of Participants who Discontinued Study Treatment due to an AE

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinue study treatment due to an AE will be presented.

    Time frame: Up to Week 204

07

Study locations

85 sites
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Apr 2026, 36 months.

Of 50 phase 2 interventional studies under Hypertension, Pulmonary, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 71. This study's 36 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2029 → May 2027, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Nov 10, 2022
StartActual
Mar 16, 2023
Primary completionActual
Apr 9, 2026
CompletionEst.
May 1, 2027was Oct 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Oct 8, 2029→May 1, 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Study completion Oct 8, 2029→May 1, 2027
    + 3 other changes: verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05612035
Responsible party
Sponsor
First posted
Nov 10, 2022
Start date
Mar 16, 2023
Primary completion
Apr 9, 2026
Completion
May 1, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Frespaciguat

Start the discussion